After numerous rounds of implementation, the core mechanism of the national centralized drug procurement system, characterized by "volume-based purchasing, price negotiation through volume, and quality as a top priority," has matured significantly. The eleventh round of centralized procurement has seen more refined selection of drug varieties, taking into account not only market size but also emphasizing the evaluation of varieties with high clinical value, urgent patient needs, and sufficient market competition, ensuring broader benefits for disease-affected populations. By adopting transparent competition rules and stringent qualification criteria, centralized procurement will continue to eliminate price inflation in the drug distribution chain, thereby substantially reducing patients' medication costs and medical insurance fund expenditures. In the long term, this standardized and large-scale procurement model will prompt pharmaceutical companies to focus more on R&D innovation and enhancing product quality, ultimately achieving a mutually beneficial outcome for patients, medical insurance relief, and industry upgrading.